Cargando…

Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy

SIMPLE SUMMARY: Classic Hodgkin lymphoma (cHL) has a high cure rate with chemotherapy, but 10–30% of patients experience relapse or refractory (R/R) disease, depending on stage and risk factors. Treatment for R/R cHL differs between young, fit patients who are eligible for high-dose chemotherapy and...

Descripción completa

Detalles Bibliográficos
Autores principales: Randall, Michael P., Spinner, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526852/
https://www.ncbi.nlm.nih.gov/pubmed/37760478
http://dx.doi.org/10.3390/cancers15184509
_version_ 1785111082664198144
author Randall, Michael P.
Spinner, Michael A.
author_facet Randall, Michael P.
Spinner, Michael A.
author_sort Randall, Michael P.
collection PubMed
description SIMPLE SUMMARY: Classic Hodgkin lymphoma (cHL) has a high cure rate with chemotherapy, but 10–30% of patients experience relapse or refractory (R/R) disease, depending on stage and risk factors. Treatment for R/R cHL differs between young, fit patients who are eligible for high-dose chemotherapy and autologous stem cell transplants and older adults who are not eligible for intensive therapies. Over the past decade, management of R/R cHL has evolved significantly following the approval of three highly active novel agents: brentuximab vedotin, nivolumab, and pembrolizumab, leading to improved cure rates and overall survival. In this review, we discuss our approach to the treatment of first relapse, maintenance therapy after transplant, relapse after transplant, and management of older adults and frail patients. Finally, we highlight emerging immunotherapies in clinical trials that hold great promise for the future. ABSTRACT: Most patients with classic Hodgkin lymphoma (cHL) are cured with combination chemotherapy, but approximately 10–20% will relapse, and another 5–10% will have primary refractory disease. The treatment landscape of relapsed/refractory (R/R) cHL has evolved significantly over the past decade following the approval of brentuximab vedotin (BV), an anti-CD30 antibody-drug conjugate, and the PD-1 inhibitors nivolumab and pembrolizumab. These agents have significantly expanded options for salvage therapy prior to autologous hematopoietic cell transplantation (AHCT), post-transplant maintenance, and treatment of relapse after AHCT, which have led to improved survival in the modern era. In this review, we highlight our approach to the management of R/R cHL in 2023 with a focus on choosing first salvage therapy, post-transplant maintenance, and treatment of relapse after AHCT. We also discuss the management of older adults and transplant-ineligible patients, who require a separate approach. Finally, we review novel immunotherapy approaches in clinical trials, including combinations of PD-1 inhibitors with other immune-activating agents as well as novel antibody-drug conjugates, bispecific antibodies, and cellular immunotherapies. Ongoing studies assessing biomarkers of response to immunotherapy and dynamic biomarkers such as circulating tumor DNA may further inform treatment decisions and enable a more personalized approach in the future.
format Online
Article
Text
id pubmed-10526852
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105268522023-09-28 Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy Randall, Michael P. Spinner, Michael A. Cancers (Basel) Review SIMPLE SUMMARY: Classic Hodgkin lymphoma (cHL) has a high cure rate with chemotherapy, but 10–30% of patients experience relapse or refractory (R/R) disease, depending on stage and risk factors. Treatment for R/R cHL differs between young, fit patients who are eligible for high-dose chemotherapy and autologous stem cell transplants and older adults who are not eligible for intensive therapies. Over the past decade, management of R/R cHL has evolved significantly following the approval of three highly active novel agents: brentuximab vedotin, nivolumab, and pembrolizumab, leading to improved cure rates and overall survival. In this review, we discuss our approach to the treatment of first relapse, maintenance therapy after transplant, relapse after transplant, and management of older adults and frail patients. Finally, we highlight emerging immunotherapies in clinical trials that hold great promise for the future. ABSTRACT: Most patients with classic Hodgkin lymphoma (cHL) are cured with combination chemotherapy, but approximately 10–20% will relapse, and another 5–10% will have primary refractory disease. The treatment landscape of relapsed/refractory (R/R) cHL has evolved significantly over the past decade following the approval of brentuximab vedotin (BV), an anti-CD30 antibody-drug conjugate, and the PD-1 inhibitors nivolumab and pembrolizumab. These agents have significantly expanded options for salvage therapy prior to autologous hematopoietic cell transplantation (AHCT), post-transplant maintenance, and treatment of relapse after AHCT, which have led to improved survival in the modern era. In this review, we highlight our approach to the management of R/R cHL in 2023 with a focus on choosing first salvage therapy, post-transplant maintenance, and treatment of relapse after AHCT. We also discuss the management of older adults and transplant-ineligible patients, who require a separate approach. Finally, we review novel immunotherapy approaches in clinical trials, including combinations of PD-1 inhibitors with other immune-activating agents as well as novel antibody-drug conjugates, bispecific antibodies, and cellular immunotherapies. Ongoing studies assessing biomarkers of response to immunotherapy and dynamic biomarkers such as circulating tumor DNA may further inform treatment decisions and enable a more personalized approach in the future. MDPI 2023-09-11 /pmc/articles/PMC10526852/ /pubmed/37760478 http://dx.doi.org/10.3390/cancers15184509 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Randall, Michael P.
Spinner, Michael A.
Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy
title Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy
title_full Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy
title_fullStr Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy
title_full_unstemmed Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy
title_short Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy
title_sort optimizing treatment for relapsed/refractory classic hodgkin lymphoma in the era of immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526852/
https://www.ncbi.nlm.nih.gov/pubmed/37760478
http://dx.doi.org/10.3390/cancers15184509
work_keys_str_mv AT randallmichaelp optimizingtreatmentforrelapsedrefractoryclassichodgkinlymphomaintheeraofimmunotherapy
AT spinnermichaela optimizingtreatmentforrelapsedrefractoryclassichodgkinlymphomaintheeraofimmunotherapy